Is There a Role for Percutaneous Ablation for Early Stage Lung Cancer? What Is the Evidence?

Curr Oncol Rep. 2021 May 5;23(7):81. doi: 10.1007/s11912-021-01072-4.

Abstract

Purpose of review: For patients with early stage non-small-cell lung cancer (NSCLC), thermal ablation (TA) has become in the least two decades an option of treatment used worldwide for patients with comorbidities who are not surgical candidates. Here, we review data published with different TA techniques: radiofrequency ablation (RFA), microwave ablation (MWA) and cryoablation. This paper reviews also the comparison that has been made between TA and stereotactic radiotherapy (SBRT).

Recent findings: A majority of retrospective studies, the absence of comparative studies, and the variety of techniques make difficult to get evident data. Nevertheless, these stand-alone techniques have demonstrated local efficacy for tumors less than 3 cm and good tolerance on fragile patients. Many recent reviews and database analyses show that outcomes after TA (mainly RFA and MWA) are comparable to SBRT in terms of survival rates. For patients who are unfit for surgery, TA has demonstrated interesting results for safety, benefits in overall survival, and acceptable local control.

Keywords: Cryoablation; Early stage lung cancer; Microwave ablation; Non small cell lung cancer; Radiofrequency ablation; Thermal ablation.

Publication types

  • Review

MeSH terms

  • Ablation Techniques / adverse effects
  • Ablation Techniques / methods*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / surgery*
  • Humans
  • Lung Neoplasms / pathology
  • Lung Neoplasms / surgery*
  • Neoplasm Staging
  • Patient Selection
  • Radiosurgery